EDP-938 Dose 1 + EDP-938 Dose 2 + Placebo + EDP-938 Dose 3 + EDP-938 Dose 4 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
RSV Infection
Conditions
RSV Infection
Trial Timeline
Oct 15, 2018 → Oct 18, 2019
NCT ID
NCT03691623About EDP-938 Dose 1 + EDP-938 Dose 2 + Placebo + EDP-938 Dose 3 + EDP-938 Dose 4 + Placebo
EDP-938 Dose 1 + EDP-938 Dose 2 + Placebo + EDP-938 Dose 3 + EDP-938 Dose 4 + Placebo is a phase 2 stage product being developed by Enanta Pharmaceuticals for RSV Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03691623. Target conditions include RSV Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03691623 | Phase 2 | Completed |
Competing Products
20 competing products in RSV Infection